Browse News
Filter News
Found 240 articles
-
Ratio Therapeutics Strengthens its Leadership Team with the Appointments of Bill Cupelo as Chief Business Officer and D. Scott Holbrook to its Board of Directors
4/2/2024
Ratio Therapeutics Inc. announced the appointments of Bill Cupelo as the company's Chief Business Officer and D. Scott Holbrook, MS, FSNMMI-TS to its Board of Directors.
-
Politics aside, both the government and the pharmaceutical industry want to bring affordable effective therapies to patients. Implementation is the obstacle. Working together is the only way to modify the IRA to do what it intends to do: benefit patients.
-
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
1/2/2024
PharmaGend Global Medical Services Pte. Ltd., jointly invested by China Medical System Holdings Limited, through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron International Limited and Healthy Goal Limited, has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte.
-
Evoke Pharma Reports Third Quarter 2023 Financial Results
11/9/2023
Evoke Pharma, Inc. announced its financial results for the third quarter ended September 30, 2023, and recent corporate developments.
-
SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform
10/31/2023
SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.
-
Mindset Pharma Announces Closing of Arrangement
10/27/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023 and October 19, 2023, Otsuka Pharmaceutical Co., Ltd. ("Otsuka")
-
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
10/26/2023
Chime Biologics, a leading CDMO that enables its partners' success in biologics, and Hope Medicine Inc. (HopeMed), a science-driven, patient-centric, clinical-stage biotech company, announced on September 28 that the companies are collaborating to develop and manufacture the first-in-class monoclonal antibody drug HMI-115.
-
Mindset Pharma Announces Receipt of Final Order
10/26/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023, October 5, 2023
-
Mindset Pharma Announces Shareholder Approval of Arrangement
10/20/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023 and September 22, 2023
-
Mindset Pharma Provides Clarifying Disclosure in Connection with Proposed Plan of Arrangement
10/6/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") wishes to clarify certain disclosure in its management information circular (the "Circular")
-
Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer
9/29/2023
Faeth Therapeutics, a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer.
-
Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order
9/25/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that, further to its press release of August 31, 2023, its management information circular (the "Circular") and related materials were mailed today,
-
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
9/20/2023
Oxford Biomedica plc announces interim results for the six months ended 30 June 2023.
-
Postdoctoral programs in industry are often overlooked by PhD candidates but they provide certain benefits over academic positions, including better pay.
-
Otsuka Pharmaceutical to Acquire Mindset Pharma
8/31/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-generation
-
Phil and RedHill Biopharma Partner to Increase Access to Talicia®
7/6/2023
Phil Inc. , a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.
-
Ora, Inc. Appoints Nate Speicher as Chief Financial Officer
6/28/2023
Ora, Inc. , the world’s leading Clinical Research Organization (CRO) for ophthalmology pharmaceutical and device development, announced today that Nate Speicher has been appointed Chief Financial Officer (CFO).
-
Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines
6/28/2023
Alloy Therapeutics announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.
-
Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder
6/22/2023
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs,
-
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
6/9/2023
PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, is pleased to report that the US Food and Drug Administration has approved a clinical trial utilizing PharmAla’s LaNeo MDMA Investigational Medical Product capsules.